June 16, 2020 / 12:04 PM / 21 days ago

Steroid dexamethasone reduces deaths among patients with severe COVID-19 - trial shows

LONDON, June 16 (Reuters) - Giving low doses of the generic steroid drug dexamethasone to patients admitted to hospital with COVID-19 reduced death rates by around a third among those with the most severe cases of infection, trial data showed on Tuesday.

The results, described as a “major breakthrough” by scientists leading the UK-led clinical trial known as RECOVERY, suggest the drug should immediately become standard care in patients treated in hospital with the pandemic disease, the researchers said.

“This is a result that shows that if patients who have COVID-19 and are on ventilators or are on oxygen are given dexamethasone, it will save lives, and it will do so at a remarkably low cost,” said Martin Landray, an Oxford University professor who is co-leading the trial.

His co-lead investigator, Peter Horby, said dexamethasone - a generic steroid widely used in other diseases to reduce inflammation - is “the only drug that’s so far shown to reduce mortality - and it reduces it significantly.”

“It is a major breakthrough,” he said.

There are currently no approved treatments or vaccines for COVID-19, the illness caused by the new coronavirus which has killed more than 431,000 globally. (Reporting by Kate Kelland and Alistair Smout, editing by Timothy Heritage)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below